Durable overall survival benefit in patients >= 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: Updated results from the valor trial Meeting Abstract


Authors: Ravandi, F.; Ritchie, E. K.; Sayar, H.; Lancet, J. E.; Craig, M.; Vey, N.; Strickland, S. A.; Schiller, G. J.; Jabbour, E. J.; Erba, H. P.; Pigneux, A.; Horst, H. A.; Recher, C.; Klimek, V. M.; Cortes, J. E.; Roboz, G. J.; Craig, A. R.; Ward, R.; Smith, J.; Kantarjian, H. M.; Stuart, R. K.
Abstract Title: Durable overall survival benefit in patients >= 60 years with relapsed or refractory AML treated with vosaroxin/cytarabine vs placebo/cytarabine: Updated results from the valor trial
Meeting Title: 58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 128
Issue: 22
Meeting Dates: 2016 Dec 3-6
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-12-02
Language: English
ACCESSION: WOS:000394446802161
PROVIDER: wos
Notes: Meeting Abstract: 903 -- Source: Wos